Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands

Salivary gland cancers comprise a wide histological spectrum with more than twenty different subtypes [1]. In 2010, a new entity of salivary gland cancer was described by Sk álová et al., characterized by the presence of the ETV6-NTRK3 fusion gene [2]. The histopathological appearance resembles secretory carcinoma of the breast, and both tumors share the ETV6-NTRK3 fusion gene, hence the proposed name was mammary analogue secretory carcinoma (MASC). In the updated 201 7 WHO classification, MASC is acknowledged and referred to as ‘secretory carcinoma’, to standardize nomenclature amongst different organ sites [1].

Source: Oral Oncology - May 11, 2018 Category: Cancer & Oncology Authors: E. Boon, M.H. Valstar, W.T.A. van der Graaf, E. Bloemena, S.M. Willems, C.A. Meeuwis, P.J. Slootweg, L.A. Smit, M.A.W. Merkx, R.P. Takes, J.H.A.M. Kaanders, P.J.T.A. Groenen, U.E. Flucke, C.M.L. van Herpen Source Type: research